Mefunidone Attenuates Tubulointerstitial Fibrosis in a Rat Model of Unilateral Ureteral Obstruction-Reference-Cited by-同舟云学术

Mefunidone Attenuates Tubulointerstitial Fibrosis in a Rat Model of Unilateral Ureteral Obstruction

Published:2015-06-04 Issue:6 Volume:10 Page:e0129283
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Liu Chunyan,Mei Wenjuan,Tang Juan,Yuan Qiongjing,Huang Ling,Lu Miaomiao,Wu Lin,Peng Zhangzhe,Meng Jie,Yang Huixiang,Shen Hong,Lv Ben,Hu Gaoyun,Tao Lijian

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference46 articles.

1. Chronic renal diseases as a public health problem: epidemiology, social, and economic implications;A. Schieppati;Kidney Int Suppl,2005

2. Prevalence of chronic kidney disease in China: a cross-sectional survey;L. Zhang;Lancet,2012

3. Mechanisms of tubulointerstitial fibrosis;M. Zeisberg;J Am Soc Nephrol,2010

4. Is kidney injury a reversible process?;C. Chatziantoniou;Curr Opin Nephrol Hypertens,2008

5. Obstructive nephropathy: insights from genetically engineered animals;J.L. Bascands;Kidney Int,2005

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mefunidone alleviates silica-induced inflammation and fibrosis by inhibiting the TLR4-NF-κB/MAPK pathway and attenuating pyroptosis in murine macrophages;Biomedicine & Pharmacotherapy;2024-09

2. Mefunidone ameliorates acute liver failure in mice by inhibiting MKK4-JNK pathway;Biochemical Pharmacology;2024-07

3. A phase I, randomized study to evaluate the safety, tolerability, and pharmacokinetics of mefunidone in healthy subjects;Frontiers in Pharmacology;2024-06-12

4. Association between the neutrophil-to-lymphocyte ratio and in-hospital mortality in patients with chronic kidney disease and coronary artery disease in the intensive care unit;European Journal of Medical Research;2024-04-30

5. Mefunidone ameliorates lipopolysaccharide-induced acute lung injury through inhibiting MAPK signaling pathway and enhancing Nrf2 pathway;International Immunopharmacology;2022-12